LitAlert ~~ GeneLit.com

    • Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer.
    • King D, Scott R.
    • OncLive. 2023 Feb 5.

    • Mitigating fear of cancer recurrence.
    • Sorscher S.
    • Breast Cancer Res Treat. 2023 Feb 3. doi: 10.1007/s10549-022-06824-9. Epub ahead of print.

    • Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice.
    • Yamai T, Ikezawa K, Sugimoto N, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Kawamura T, Kunimasa K, Yamamoto S, Wakamatsu T, Hayashi T, Kukita Y, Fujisawa F, Inoue T, Yamaguchi Y, Yamasaki T, Honma K, Ohkawa K.
    • Cancers (Basel). 2023 Feb 3;15(3):970. doi: 10.3390/cancers15030970.

    • Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
    • Wahner A.
    • OncLive. 2023 Feb 1.

    • The Role of PARP Inhibitors in Non-BRCA Mutated Breast Cancer.
    • Ballinger TJ.
    • Medscape Oncology. Decision Point. 2023 Jan 13.

    • Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    • Kim ET, Jeong HE, Yoon HJ, Kim KH, Suh DS.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):66-70. doi: 10.1016/j.tjog.2022.07.010.